Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 12 December 2017

NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES

NEOVACS    

Published: 07:00 CET 12-12-2017 /GlobeNewswire /Source: NEOVACS / : ALNEV /ISIN: FR0004032746


 

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE

 

NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY

 FOR IFNalpha KINOID IN TYPE 1 DIABETES

 

Company intends to continue preclinical development in this indication in 2018

 

Paris and Boston, December 12th 2017, 07:00 am CET - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced positive initial results from its ongoing proof-of-concept (PoC) preclinical studies with IFNalpha Kinoid for the treatment of Type 1 Diabetes (T1D).

The ongoing PoC preclinical studies in Type 1 Diabetes in non-obese diabetic (NOD) mice[1], conducted in collaboration with Dr. Agnès Lehuen and Pr. Christian Boitard, from the department of Immunology of Diabetes at the Hospital Cochin in Paris, have confirmed:
 
  • A strong production of neutralizing antibodies to IFNalpha following IFNalpha Kinoid administration
  • A twice higher preservation of Langerhans islets[2]  is observed in mice treated with IFNalpha Kinoid compared to the control groups.
  • A notable delay in the onset of Type 1 Diabetes in relation to the persistence of anti-IFNalpha neutralizing antibodies
"In this initial preclinical study for the treatment of type 1 diabetes, we observed a delay in the triggering of the pathology, which was maintained for several weeks." said Miguel Sieler, Chief Executive Officer of Neovacs. "Additionally, the protection of Langerhans islets suggests that the IFNalpha Kinoid vaccine could have a preventive action. Based on these promising results, we look forward to finalizing our trials, with the goal of initiating a clinical development program in type 1 diabetes in the near future."
 
Neovacs expects to complete this study in 2018 in order to fully evaluate the therapeutic potential of IFNalpha Kinoid in T1D. These final results will guide the protocol of Neovacs' first clinical study in this indication.
 

IFNalpha Kinoid is an anti-interferon-alpha vaccine that is currently in clinical development in several indications. Neovacs previously demonstrated in its Phase I/IIa[3] clinical study of IFNalpha Kinoid in Lupus that the persistence of neutralizing antibodies for several years can be achieved with the Company's vaccine candidate and is also capable of neutralizing the Interferon signature. A Phase IIb study is currently ongoing with IFNalpha Kinoid for the treatment of Lupus.

 

About Type 1 Diabetes

Type 1 Diabetes is an autoimmune disease which is foreseen to affect 25 million people in the world by the year 2020 with growing incidence worldwide (+3%pa). Source WHO. This disease may cause severe and even life threatening complications and has no curative treatment. Patients have to monitor their glycaemia throughout the day and are treated with multiple insulin injections over their lifetime.

 

About Neovacs Technology

Neovacs targets pathologies associated with an overproduction of endogenous cytokines. This technology is based on active immunotherapy to generate an immune response through the administration of an immunogenic complex involving the target cytokine to a carrier protein. The intramuscular injection of this Kinoid induces an immune response and stimulates the production of polyclonal antibodies against the target cytokines. It is thus possible to block cytokine overproduction and its pharmacological effects. Several autoimmune and inflammatory diseases (Type 1 diabetes, systemic lupus erythematosus, psoriasis, etc.) are characterized by a disorder of cytokines that are found produced in excess (ex: IFNalpha). This overproduction will promote inflammation and dysregulation of the immune system.

 

About Neovacs

Listed on Euronext Growth Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

 

Contacts

NEOVACS - Corporate Communication & Investor Relations

Charlène Masson

+33 1 53 10 93 00

cmasson@neovacs.com

LIFESCI ADVISORS- Investor Relations / Financial Communications

Chris Maggos

chris@lifesciadvisors.com

+41 79 367 6254



[1] Non-obese Diabetic (NOD), Leiter, Curr Protoc Mouse Biol. 2013

[2] Langerhans islets or pancreatic islets: cells capable of producing insulin

[3] Lauwerys et al., Arthritis & Rheumatism 2013 ; Ducreux et al., Rheumatology 2016



Press release



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Neovacs, 3-5 impasse Reille, Paris FR-75014, France
If you would like to unsubscribe and stop receiving these e-mails click here.